IP Library › Granted Patent US 12,534,428
Granted Patent B2
US 12,534,428 · App. 18/113,047 · Granted Jan 27, 2026

Non-distillative process for manufacturing high purity amphetamines

Inventors: Harold Meckler (Albany, NY); Darryl Cleary (Albany, NY); Karl Popp (Albany, NY); Heidi Schlager (Albany, NY); Mozhgan Navidi (Albany, NY); Joshua Malone (Albany, NY)
Assignee: Pharmapotheca A, Inc.
C07C231/14C07C209/24C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,428
App. No.
18/113,047
Granted
Jan 27, 2026
Kind
B2
Abstract

The invention provides a non-distillative process for manufacturing amphetamine and substituted amphetamines, comprising obtaining a highly pure phosphoramidate compound, converting the highly pure phosphoramidate compound to an amphetamine sulfate compound, concentrating the amphetamine sulfate compound in isopropanol, and then salting out the amphetamine compound directly to obtain an amphetamine salt, the amphetamine salt selected from amphetamine saccharate, amphetamine sulfate, amphetamine aspartate, alkyl-amphetamine saccharate, alkyl-amphetamine sulfate, alkyl-amphetamine aspartate, aryl-amphetamine saccharate, aryl-amphetamine sulfate, aryl-amphetamine aspartate, and mixtures thereof.

Claims (41)

1 . A non-distillative process for manufacturing a substituted sulfate amphetamine, comprising: adding aqueous H 2 SO 4 to a (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl) phosphoramidate compound, warming to 80° C., cooling to 20° C., washing in isopropanol or toluene, combining organic layers, and collecting a solid by filtration, wherein the solid is (S,R, S,S, R,R or R,S) (dialkyl or diaryl)(1-phenylpropan-2-amine) sulfate.

2 . The process of claim 1 , wherein the substituted amphetamine sulfate is dexamphetamine sulfate and the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl) phosphoramidate compound is (S or R,S) (diethyl) (1-phenylpropan-2-yl) phosphoramidate.

3 . The process of claim 1 , further comprising the steps of concentrating the substituted amphetamine sulfate in isopropanol, and then salting out the substituted amphetamine compound directly to obtain a substituted amphetamine salt, the substituted amphetamine salt selected from a substituted amphetamine saccharate, a substituted amphetamine sulfate, a substituted amphetamine aspartate, an alkyl-amphetamine saccharate, an alkyl-amphetamine sulfate, an alkyl-amphetamine aspartate, an aryl-amphetamine saccharate, an aryl-amphetamine sulfate, an aryl-amphetamine aspartate, and mixtures thereof.

4 . The process of claim 1 , wherein the substituted amphetamine sulfate is >99% pure.

5 . The process of claim 3 , wherein the substituted amphetamine salt is selected from dextroamphetamine saccharate, dextroamphetamine sulfate, or dextroamphetamine aspartate.

6 . The process of claim 1 , wherein the substituted amphetamine sulfate is optically active or a racemic mixture thereof.

7 . The process of claim 1 , wherein the substituted amphetamine sulfate is selected from the group consisting of a dextroamphetamine salt, a levoamphetamine salt, or a mixture thereof.

8 . The process of claim 1 , where the substituted amphetamine sulfate is formulated in a pharmaceutically acceptable composition.

9 . The process of claim 1 , further comprising the step of washing with methyl-tert-butyl-ether (MTBE) after washing with isopropanol or toluene but before combining organic layers.

10 . The process of claim 1 , wherein the phosphoramidate is diethyl-(1-phenylpropan-2-y) phosphoramidate and is optically active.

11 . The process of claim 1 , wherein the phosphoramidate is diethyl(S)-(1-phenylpropan-2-y) phosphoramidate, diethyl (R)-(1-phenylpropan-2-y) phosphoramidate or mixtures thereof.

12 . The process of claim 1 , wherein the substituted amphetamine is optically active, dextrorotatory, levorotatory, or racemic.

13 . The process of claim 1 , wherein the purity of the substituted amphetamine sulfate is not less than 98% on a weight basis.

14 . The process of claim 1 , wherein the substituted amphetamine sulfate comprises a regiospecific impurity β-methylphenethylamine present at a level of less than 0.1% on a weight basis.

15 . The process of claim 1 , further comprising wherein the substituted amphetamine sulfate is converted to lisdexamfetamine.

16 . A process, comprising:

(i) reacting (S or R,S) (dialkyl or diaryl)(1-phenylpropan-2-yl)phosphoramidate, with 3N HCl at 80° C. for 1.5 h, cooling to room temperature, adding toluene and agitating, and removing an organic layer;

(i reacting the organic layer with 50% NaOH to adjust pH to 13, agitating with methyl-tert-butyl-ether (MTBE), separating an aqueous layer from an organic layer, washing the organic layer with MTBE;

(iii) diluting the organic layer with isopropanol, warming to 45-50° C., and concentrating under vacuum to obtain (S or R,S) (dialkyl or diaryl)(1-phenylpropan-2-yl)amine dissolved in isopropanol;

(iv) adding H 2 SO 4 aq and isopropanol to the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine dissolved in isopropanol while maintaining 45-50° C.;

(v) adding isopropanol, and warming to 80° C. for 1 h, cooling to 50° C. over 6 h, 20° C. over 5 h, and maintaining at 20° C. for 4 h;

(vi) adding isopropanol and cooling to 5° C., agitating for 6 h;

(vii) collecting a solid by filtration, washing with cold isopropanol/water;

wherein the solid is a (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine [H 2 SO 4 ] having a purity of >99.9%.

17 . The process of claim 16 , wherein the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine is converted to a saccharic acid salt or a aspartic acid salt, the steps comprising:

(xi) making a slurry in water at RT of the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine, adding 50% aq NaOH, stir 0.5 h, agitating 0.5 h w/MTBE, and obtaining an organic layer, diluting the organic layer with isopropanol, warming to 50° C., concentrating under vacuum, and cooling to RT;

(xii) making slurry from a saccharate or aspartate, cooling the slurry to 5° C. and treating with concentrated H 2 SO 4 aq., agitating for 0.25 h at 5° C., warming to RT, stirring for 1 h, diluting with isopropanol and agitating for 1 h, and filtering to obtain a saccharic acid filtrate or aspartic acid filtrate;

(xiii) adding saccharic acid filtrate or aspartic acid filtrate to the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine to obtain a slurry, agitating for 1.5 h at RT, gradually warming and holding at 55° C., slowly adding water to yield clear solution, agitating the clear solution for 2 h, reducing the heat to 45° C. over 3 h, cooling to 5° C. over 5 h, holding for 7 h, and obtaining a white solid by filtration;

wherein the white solid is >99.9% chiral (dex) isomer of (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine or (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine.

18 . A process, comprising:

(i) reacting (S or R,S) (dialkyl or diaryl)(1-phenylpropan-2-yl)phosphoramidate, with H 2 SO 4 aq and warming to 80° C. for 1 h, cooling to 20° C.;

(ii) adding toluene, concentrating under vacuum, wash/repeat until water wt. is 0.11 weight %;

(iii) adding toluene, warming to 80° C., agitating 1 h, cooling to 50° C. over 2 h, cooling to RT, and holding at RT 4-24 h;

(iv) cooling to 5° C., and holding for 12 h;

(v) collecting a solid by filtration;

wherein the solid is a (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine [H 2 SO 4 ] having a purity of >99.92% AUC.

19 . The process of claim 18 , wherein the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine is converted to a saccharic acid salt or a aspartic acid salt, the steps comprising:

(vi) making a slurry in water at RT of the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine, adding 50% aq NaOH, stir 0.5 h, agitating 0.5 h w/MTBE, and obtaining an organic layer, diluting the organic layer with isopropanol, warming to 50° C., concentrating under vacuum, and cooling to RT;

(vii) making slurry from a saccharate or aspartate, cooling the slurry to 5° C. and treating with concentrated H 2 SO 4 aq., agitating for 0.25 h at 5° C., warming to RT, stirring for 1 h, diluting with isopropanol and agitating for 1 h, and filtering to obtain a saccharic acid filtrate or aspartic acid filtrate;

(viii) adding saccharic acid filtrate or aspartic acid filtrate to the (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine to obtain a slurry, agitating for 1.5 h at RT, gradually warming and holding at 55° C., slowly adding water to yield clear solution, agitating the clear solution for 2 h, reducing the heat to 45° C. over 3 h, cooling to 5° C. over 5 h, holding for 7 h, and obtaining a white solid by filtration;

wherein the white solid is >99.9% chiral (dex) isomer of (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine or (S or R,S) (dialkyl or diaryl) (1-phenylpropan-2-yl)-amine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: MALONE, JOSH; NAVIDI, MOZHGAN; SCHLAGER, HEIDI
To: CURIA GLOBAL, INC.
Reel/Frame 069623/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: CURIA GLOBAL, INC.
To: PHARMAPOTHECA A, INC.
Reel/Frame 069624/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2024
From: MECKLER, HAROLD; POPP, KARL; CLEARY, DARRYL
To: PHARMAPOTHECA A, INC.
Reel/Frame 066270/0542 →
Continuity (1)
Related Publication 20240286993A1 · Aug 29, 2024
References Cited (73)
US 6399828B1 · Boswell et al. · 2002 [cited by applicant]
US 7662787B2 · Mickle · 2010 [cited by applicant]
US 7705184B2 · Buenger et al. · 2010 [cited by applicant]
US 8487134B2 · Meudt et al. · 2013 [cited by applicant]
US 9278904B2 · Meckler et al. · 2016 [cited by applicant]
US 9321794B2 · Meckler et al. · 2016 [cited by applicant]
US 9657041B2 · Meckler et al. · 2017 [cited by applicant]
US 10087202B2 · Meckler et al. · 2018 [cited by applicant]
US 11123310B2 · Popp et al. · 2021 [cited by applicant]
US 20170210768A1 · Meckler et al. · 2017 [cited by applicant]
WO WO2007054105A2 · 2007 [cited by applicant]
WO WO2011084098A1 · 2011 [cited by applicant]
WO WO2017147375 · 2017 [cited by applicant]
Written Opinion of Int'l. Search Authority for PCT/US2015/017265, Feb. 2015. [cited by applicant]
Int'l. Search Report for PCT/US2015/017265, Feb. 2015. [cited by applicant]
Written Opinion of Int'l. Search Authority for PCT/US2015/017266, Feb. 2015. [cited by applicant]
Int'l. Search Report for PCT/US2015/017266, Feb. 2015. [cited by applicant]
Int'l. Preliminary Report for PCT/US2020/020713, Mar. 2020. [cited by applicant]
Search History for PCT/US2020/020713, Mar. 2020. [cited by applicant]
Int'l. Search Report for PCT/US2020/020713, Mar. 2020. [cited by applicant]
Written Opinion of Int'l. Search Authority for PCT/US2020/020713, Mar. 2020. [cited by applicant]
PV59265 French Patent 5857M, Apr. 1966. [cited by applicant]
Kojima, Scifinder CAS Registry 1485-13-8 for 2-methyl-3-phenyl-aziridine, Kojima 1959 et al., 1959. [cited by applicant]
Allen and Ely, Synthetic Methods for Amphetamines, Crime Scene magazine, p. 15-25 Spring 2011, 2011. [cited by applicant]
Angew Alkylation of Diethyl Phosphoramidates—A Simple Route from Primary to Secondary Amines, Chem Int ed 1977, 1977. [cited by applicant]
Mekenyan, Scifinder 2010: 1165579 ACS, Aziridine Use of Genotoxicity Information . . . , Chem Res Tox vol. 23 Issue 10 pp. 1519- 1540, 2010, 2010. [cited by applicant]
Sakurai, Scifinder 2000- 630740 ACS, Aziridine Recommendation of Occupational exposure limits, J Occup Health, vol. 42, Issue 4, pp213-228, 2000, 2000. [cited by applicant]
Koleva, Scifinder 2011-1058228 ACS, Modelling of Acute Oral . . . aziridine toxicity, Toxicology InVitro, vol. 25, Issue 7, pp. 1281-1293, 2011, 2011. [cited by applicant]
Lambrechts, Leuckart-specific impurities in amphetamine, Bulletin on Narcotics, UNODC Everywhere, pp. 47-57, Jan. 1, 1984, 1984. [cited by applicant]
D'Ambra, Scifinder Search Results for D'Ambra patents (allergy drugs, regioselectivity) Accession 2002-52000, from US20020007068, 1999, 1999. [cited by applicant]
Rege et al. Drug Metabolism and Disposition, VOI 30 No. 12, pp. 1337-1343, Irreversible Inhibition of CYP2D6 by (−) Chloroephedrine (impurity), 2002, 2002. [cited by applicant]
EMEA Committee for Medical Products, Grignard Solvents Committee, Feb. 10, 2005, pp. 1-7, 2005. [cited by applicant]
FDA CDER Guidance for Industry, (genotox guidance) Dec. 2008, 2008. [cited by applicant]
Skinner, Methamphetamine Synthesis via Hydriodic . . . , Forensic Sci Int'l, 48 (1990) 123-134, red phos method, 1990. [cited by applicant]
Anderson, Development of a Harmonised Method for Profiling . . . , Forensic Sci Int'l 169 (2007) pp. 50-63, GC method, 2007. [cited by applicant]
Anderson, Development of a Harmonised Method for Profiling . . . , Forensic Sci Int'l 169 (2007) pp. 64-76, GC method, 2007. [cited by applicant]
Stojanovska, A Review of Impurity Profiling . . . , Forensic Sci Int'l 224 (2013) 8-26, 2013. [cited by applicant]
Power, An Unusual Presentation of Customs Seizure, Forensic Sci Int'l 234 (2014) e10-e13, 2014. [cited by applicant]
Barker, A Study of the Use of Ephedra, Forensic Sci Int'l 166 (2007) 102-109, 2007. [cited by applicant]
Humfrey, Keeping Afloat in a Sea of Impurities, Global Safety Assessment, Astra Zeneca Jul. 6, 2007, 2007. [cited by applicant]
EMEA Solvent (Grignard) impurities, ICH Topic Q3C (R4), pp. 1-22, 2010, 2010. [cited by applicant]
Funel and Abele, Diels Alder Reactions Part 1, Angewandte Reviews, Angew. Chem Int 2013 vol. 52, 1-44, 2013, 2013. [cited by applicant]
Funel and Abele, Diels Alder Reactions Part 2, Angewandte Reviews, Angew. Chem Int 2013 vol. 52, 1-44, 2013, 2013. [cited by applicant]
Funel and Abele, Diels Alder Reactions Part 3, Angewandte Reviews, Angew. Chem Int 2013 vol. 52, 1-44, 2013, 2013. [cited by applicant]
Funel and Abele, Diels Alder Reactions Part 4, Angewandte Reviews, Angew. Chem Int 2013 vol. 52, 1-44, 2013, 2013. [cited by applicant]
Stephans, Substituted Aziridines, Prep and Properties, J Chem Engin, vol. 8, No. 4, pp. 625-626, Oct. 1963, 1963. [cited by applicant]
Stephans, Relative rates of Reaction and Direction of Ring Opening, J Chem Engin, vol. 14, No. 1, pp. 114-115, Jan. 1969, 1969. [cited by applicant]
Borkovec, Insect Chemosterilants, Aziridnylphosphine Oxides, JMedChem vol. 9, pp. 522-526, Feb. 1966, 1966. [cited by applicant]
Hata, Fragmentation Reaction of Ylide, JACS vol. 98-19, pp. 6033- 6036, Sep. 1976, 1976. [cited by applicant]
Poshkus, the Reaction of Neutral Esters of Trivalent Phosphorus Acids, JACS vol. 79, pp. 6127-6129, 1957, 1957. [cited by applicant]
Jessing, Aziridines in Synthesis, Baran Lab Jan. 2007, 2007. [cited by applicant]
Hassner, A.; Galle, J. E.; “Ring Opening of Aziridine Phosphonates. Correlation of Structure, Nuclear Magnetic Resonance Spectra and Reactivity” J. Org. Chem., 1976, 41, 2273-2276, 1976. [cited by applicant]
Stromberg, Comparative GC Analysis, J Chromatography 106 (1975) 335-342, amphet sulfate, 1975. [cited by applicant]
Lambrechts, Profiling of Impurities in Illicit Amphetamine, 1986 J Chromatography vol. 369 (1976) pp. 365-377 HPLC impurities, 1986. [cited by applicant]
Allen, Methamphetamines from Ephedrine, J Forensic Sci vol. 32, No. 4, Jul. 1987, pp. 953-962, 1987. [cited by applicant]
Milstein, Friedel Crafts Reactions of Htree Member Heterocycles, J Het Chem vol. 5, pp. 339-241, Mar. 1968, 1968. [cited by applicant]
Hassner, Regiospecificity: A Useful Terminology, JOC vol. 33, No. 7 pp. 2684-2686 Jul. 1968, 1968. [cited by applicant]
Todd, Aneurin, A Synthesis of Thiochrome, J Chem Soc 1936, pp. 1601-1605, 1936. [cited by applicant]
Hider, Prep of Evidence in Amphet Prosecutions, J Forensic Sci pp. 75-79 1960's, 1960. [cited by applicant]
Anandasankar , Scifinder 7763-71-5, referring to WO 2011 130726, priority to US 2011-32804, and 2010-61325236, 2011. [cited by applicant]
Osowska-Pacewicka, N-Phosphorylated Aziridines—new reagents for electrophilic amination, Polish J Chem 68-6 pp. 1263-1264 1994, 1994. [cited by applicant]
Pramanik, An Efficient Scalable Process for Benzphetamine HCI, JACS J Org Process Res Dev 2014 vol. 18 pp. 495-500, 2014. [cited by applicant]
Giles, A Improved Process for the N-Alkylation of Indoles Using Chiral N-Protected 2-Mehtylaziridines J. Org Proc Res Dev, 2003 vol. 7, pp. 22-24, 2003. [cited by applicant]
Snodin, Potentially Mutagenic Impurities, J Org Process Res Dev 2014, vol. 18, pp. 836-839 Racemic, 2014. [cited by applicant]
Raman, Regulatory Expectations Towards Genotoxic, J Org Process Res Dev 2014 vol. 18 pp. 834-835, 2014. [cited by applicant]
Teasdale, Regulatory Highlights, J Org Process Res Dev 2014 vol. 18, 458-472, 2014. [cited by applicant]
Jawahar, Direct Stereospecific Synthesis of Unprotected N-H and N-Me Aziridines from Olefins, Sciences 343, 61 pp. 61-65, 2014, 2014. [cited by applicant]
Koziara, A.; Oleiniczak, B.; Osowska, K.; Zwierzak, A.“Phosphoramidomercuration-Demercuration: A Simple Two-Step Conversion of Alkenes into Alkanamines” Synthesis 1982, 918-920, 1982. [cited by applicant]
Osowska-Pacewicka, Reactions of N-Phosphorylated Aziridines with Dianions Derived from Ethyl Aceotacetate and 1,3 Diketones, Synth. Commun. Org. Chem. vol. 28:7, 1127-1137 1998, 1998. [cited by applicant]
Gajda, Synthesis of Primary sec-Alkylamines via Nucleophilic Ring-opening of N-Phosphorylated Aziridines, Tetrahedron Letters, 53:13, 4935-4946 1997, 1997. [cited by applicant]
Breque, A.; Savignac P.; “Derives Phosphoryles des Methyl-1 et Methyl-2 Amino-2 Ethanethiols” Phosphorus and Sulfur. 1980, 89-94, 1980. [cited by applicant]
US Pharmacopeia; “Dextroamphetamine Sulfate Tablets” Official Monographs. 2014, 2570-2571, 2014. [cited by applicant]
Herbrink, M.; Thijssen, B.; Hillebrand, M.J.X.; Rosing, H.; Schellen, J.H.M.; Nuijen, B.; Beijnen, J.H.; “Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the qua… [cited by applicant]